Alle Studien
RekrutierungPhase IIIInterventionell

Astria STAR-0215-302 trial for Navenibart in Hereditary Angioedema

Researchers are studying a new medicine called navenibart for hereditary angioedema (HAE), a condition causing unpredictable swelling attacks. These attacks can be very painful and disabling. Navenibart is designed to help prevent these attacks. This study, called ORBIT-EXPANSE, is particularly interested in checking the safety and how well people cope with navenibart over a long period, up to five years. It's for adults and teenagers (aged 12 and older) who have already taken part in a previous navenibart trial (ALPHA-ORBIT). The information gathered will help improve future treatments for HAE, even if there's no direct benefit for every individual participant.

Auf einen Blick

Status
Rekrutierung
Phase
Phase III
Sponsor
Astria Therapeutics, Inc (USA)
Einschreibeziel
145
Starten
12. Feb 2026
Geschätzte Fertigstellung
31 Dez 2026

Worum geht es in dieser Studie?

Hereditary angioedema (HAE) is a rare condition that causes sudden and painful swelling. These swelling attacks can affect different parts of the body, like the face, arms, legs, and even the throat, which can be very serious. Currently, people with HAE take medicines to stop attacks once they start, or to prevent them from happening. However, sometimes these treatments need to be taken very often, which can be difficult for patients.

This study is looking at a new medicine called navenibart. Navenibart is a type of medicine that works with your body's immune system. It aims to prevent HAE attacks by blocking a specific natural process in the body that causes the swelling. Early studies have suggested that navenibart could be helpful in preventing these attacks. The company that makes navenibart, Astria Therapeutics, wants to learn more about how it works in people with HAE.

The main goal of this study, called ORBIT-EXPANSE, is to understand how safe navenibart is and how well people tolerate it when taken over a long time. This includes both adults (18 and older) and teenagers (12-17 years old). Participants will be in the study for up to five years. The information gathered from this research will help doctors and scientists better understand HAE and develop more effective and convenient treatments in the future.

Wichtige Erkenntnisse

  • New medicine (navenibart) for hereditary angioedema (HAE) is being studied.
  • Aims to check long-term safety and how well people tolerate the medicine.
  • For adults and teenagers (12+) who completed a previous navenibart study (ALPHA-ORBIT).
  • Participants will receive navenibart through under-the-skin injections.
  • Study could last up to five years.
  • Results will help improve future HAE treatments.

Wer könnte berechtigt sein?

This study is for people who have hereditary angioedema (HAE) and have already taken part in a previous study for navenibart called ALPHA-ORBIT (STAR-0215-301). You would have either completed the ALPHA-ORBIT study or left it early but still received at least two doses of the study medicine and had at least two months of follow-up after the second dose.

You cannot take part if you have been in another medical study (apart from ALPHA-ORBIT) in the last 30 days, or if you've had certain study medicines (other than navenibart) recently. Also, if you've taken certain blood pressure medicines (called ACE inhibitors) or hormone-containing medicines (like some contraceptives or hormone replacement therapy) in the last 30 days, you won't be able to join.

Finally, if you know you are allergic to any of the ingredients in navenibart, this study would not be suitable for you. The study is open to both men and women, aged 12 years and older.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. I have hereditary angioedema (HAE).
  2. I previously took part in the ALPHA-ORBIT study (STAR-0215-301).
  3. I completed the ALPHA-ORBIT study or met specific criteria if I left it early.
  4. I have not taken part in another recent medical study (apart from ALPHA-ORBIT).
  5. I have not recently used certain blood pressure or hormone medicines.
  6. I am not allergic to any ingredients in navenibart.
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you join this study, your involvement could last for up to five years. All participants will receive the study medicine, navenibart, which is given as an injection just under the skin.

For adults who were in the ALPHA-ORBIT study, the first part of this new study will last at least six months. If you received navenibart in ALPHA-ORBIT, you'll continue with the same dose. If you received a placebo (a dummy treatment) in ALPHA-ORBIT, you'll start receiving 600mg of navenibart every three months. After this first part, adults may be able to discuss changing their dose with the study doctors. Teenagers in the study will continue to receive navenibart at the same dose they had in the ALPHA-ORBIT study.

Potenzielle Risiken und Vorteile

It's important to know that taking part in this study may not directly improve your HAE or provide a personal medical benefit. Your HAE might get better, stay the same, or even get worse. However, the information learned from this study is very valuable and will help researchers better understand HAE and develop improved treatments for everyone with the condition in the future. As with any medicine, there is a possibility of side effects from navenibart, but the study aims to carefully monitor and understand these over the long term. You are free to withdraw from the study at any time.

Standorte (6)

Einige Standortangaben sind ungefähr. Wir arbeiten daran, dies zu verbessern — bitte überprüfen Sie die Angaben mit dem Versuchsteam, bevor Sie reisen.
  • Frimley Health NHS Foundation Trust
    Nur Stadt
    Camberley, England
  • Barts Health NHS Trust
    Nur Stadt
    London, England
  • North Bristol NHS Trust
    Nur Stadt
    Bristol, England
  • Royal Free London NHS Foundation Trust
    Nur Stadt
    London, England
  • University Hospitals Plymouth NHS Trust
    Nur Stadt
    Plymouth, England
  • Cambridge University Hospitals NHS Foundation Trust
    Nur Stadt
    Cambridge, England

Häufige Fragen

What is hereditary angioedema (HAE)?

HAE is a rare genetic condition that causes sudden, unpredictable, and often painful attacks of swelling in different parts of the body.

What does navenibart do?

Navenibart is a new medicine being studied to help prevent HAE attacks by blocking a natural process in the body that leads to swelling.

How is navenibart given?

Navenibart is given as an injection just under the skin, using a small needle.

Wie lange werde ich an der Studie teilnehmen?

If you join, your participation could last for up to five years.

Will I definitely receive the study medicine?

Yes, all participants in this study will receive navenibart.

Wie Sie mehr erfahren können

. Clinical Trial Inquiries

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "Astria STAR-0215-302 trial for Navenibart in Hereditary Angi… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.